BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17055096)

  • 21. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer.
    Givens DJ; Karnell LH; Gupta AK; Clamon GH; Pagedar NA; Chang KE; Van Daele DJ; Funk GF
    Arch Otolaryngol Head Neck Surg; 2009 Dec; 135(12):1209-17. PubMed ID: 20026818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presurgical cytoreduction of oral cancer using intra-arterial cisplatin and limited concomitant radiation therapy (Neo-RADPLAT).
    Robbins KT; Samant S; Vieira F; Kumar P
    Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):28-32. PubMed ID: 14732764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer.
    Rades D; Stoehr M; Meyners T; Bohlen G; Nadrowitz R; Dunst J; Schild SE; Wroblewski J; Albers D; Schmidt R; Alberti W; Tribius S
    Strahlenther Onkol; 2008 Apr; 184(4):198-205. PubMed ID: 18398584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemoradiation therapy using radiotherapy, systemic chemotherapy with 5-fluorouracil and nedaplatin, and intra-arterial infusion using carboplatin for locally advanced head and neck cancer - Phase II study.
    Fuwa N; Kodaira T; Furutani K; Tachibana H; Nakamura T; Daimon T
    Oral Oncol; 2007 Nov; 43(10):1014-20. PubMed ID: 17258494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoradiation for advanced head and neck cancer: potential for improving results to match those of current treatment modalities for early-stage tumors--long-term results of hyperfractionated chemoradiation with carbogen breathing and anemia correction with erythropoietin.
    Villar A; Martinez JC; de Serdio JL
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1382-8. PubMed ID: 18037586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of head and neck cancers: issues for clinical pharmacists.
    Scarpace SL; Brodzik FA; Mehdi S; Belgam R
    Pharmacotherapy; 2009 May; 29(5):578-92. PubMed ID: 19397465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.
    Langendijk JA; Doornaert P; Verdonck-de Leeuw IM; Leemans CR; Aaronson NK; Slotman BJ
    J Clin Oncol; 2008 Aug; 26(22):3770-6. PubMed ID: 18669465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer.
    Rengan R; Pfister DG; Lee NY; Kraus DH; Shah JP; Shaha AR; Ben-Porat LS; Zelefsky MJ
    Am J Clin Oncol; 2008 Oct; 31(5):465-9. PubMed ID: 18838883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer.
    Rades D; Fehlauer F; Sheikh-Sarraf M; Kazic N; Basic H; Poorter R; Hakim SG; Schild SE; Dunst J
    Head Neck; 2008 Feb; 30(2):235-41. PubMed ID: 17657790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer.
    Pehlivan B; Luthi F; Matzinger O; Betz M; Dragusanu D; Bulling S; Bron L; Pasche P; Seelentag W; Mirimanoff RO; Zouhair A; Ozsahin M
    Ann Surg Oncol; 2009 May; 16(5):1337-43. PubMed ID: 19280263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.
    Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3).
    Bjarnason GA; Mackenzie RG; Nabid A; Hodson ID; El-Sayed S; Grimard L; Brundage M; Wright J; Hay J; Ganguly P; Leong C; Wilson J; Jordan RC; Walker M; Tu D; Parulekar W;
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):166-72. PubMed ID: 18805649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer.
    Jellema AP; Slotman BJ; Doornaert P; Leemans CR; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):751-60. PubMed ID: 17560735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
    Langer CJ; Harris J; Horwitz EM; Nicolaou N; Kies M; Curran W; Wong S; Ang K
    J Clin Oncol; 2007 Oct; 25(30):4800-5. PubMed ID: 17947728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
    Koiwai K; Shikama N; Sasaki S; Shinoda A; Kadoya M
    Jpn J Clin Oncol; 2009 Jul; 39(7):413-7. PubMed ID: 19383615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
    Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preliminary report of pulsed dose rate brachytherapy in head-and-neck cancer.
    Ziemlewski A; Zienkiewicz J; Serkies K; Badzio A
    Strahlenther Onkol; 2007 Sep; 183(9):512-6. PubMed ID: 17762926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Choi YJ; Chung JS; Shin HJ; Cho GJ; Wang SG; Lee BJ; Cho BM; Joo YD; Sohn CH
    J Laryngol Otol; 2008 Aug; 122(8):848-53. PubMed ID: 18047761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.